logo

For the Inventor, By the Inventor

Hyderabad Telangana, India

Mylan Laboratories Limited

Calculating rank
USPTO Granted Patents = 42

% Expired Patents = 35.7



Trademarks = 4

Forward Citations = 19

Loading Chart...
Loading Chart...

169 inventors (with patents filed for the assignee):

goldMedal Ramakoteswara Rao Jetti (10 out of 10 patents)

silverMedal Debashish Datta (5 out of 7 patents)

bronzeMedal Anjaneyaraju Indukuri (4 out of 4 patents)

4.  Vijaya Krishna Ravi (4 out of 4 patents)

5.  Ramesh Dandala (4 out of 26 patents)

6.  Lakshmana Rao Vadali (4 out of 4 patents)

7.  Vinayak Gore (4 out of 4 patents)

8.  Aggi Ramireddy Bommareddy (4 out of 4 patents)

9.  Hemant Malhari Mande (3 out of 3 patents)

10.  Neelima Bhagavatula (3 out of 3 patents)

11.  Vipin Kumar Kaushik (3 out of 6 patents)

12.  Sureshbabu Jayachandra (3 out of 4 patents)

13.  Arabinda Sahu (3 out of 5 patents)

14.  Dnyandeo Punde (2 out of 2 patents)

15.  Jeffrey P Smith (2 out of 6 patents)


Core Competencies:
Pharmaceutical Composition
Polymorphic Forms
Preparation Process
Meloxicam
Dolutegravir
Sofosbuvir
Ezetimibe
HIV Therapy
Aliskiren
Valsartan
Candesartan
Roflumilast

42 patents:

1. 12740988 - Pharmaceutical composition comprising meloxicam (2026-09-22),
2. 12648912 - Pharmaceutical composition comprising meloxicam (2026-06-09),
3. 12398100 - Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (2025-08-26),
4. 11466031 - Polymorphic forms of bictegravir and its sodium salt (2022-10-11),
5. 10800777 - Polymorphic forms of VENCLEXTA (2020-10-13),
6. 10738071 - Polymorphic forms of sofosbuvir (2020-08-11),
7. 10730888 - Process for the preparation of dolutegravir (2020-08-04),
8. 10710999 - Polymorph of an intermediate for palbociclib synthesis (2020-07-14),
9. 10562866 - Amorphous trisodium sacubitril valsartan and a process for the preparation thereof (2020-02-18),
10. 10487067 - Process for the preparation of velpatasvir (2019-11-26),
11. 10479782 - Forms of lumacaftor and processes for the preparation thereof (2019-11-19),
12. 10391178 - Premix of crystalline raltegravir potassium salt and a process for the preparation thereof (2019-08-27),
13. 10369108 - Hot melt granulation formulations of poorly water-soluble active agents (2019-08-06),
14. 10344009 - Process for the preparation of sofosbuvir (2019-07-09),
15. 10100075 - Process for the preparation of sofosbuvir (2018-10-16),
Company Overview
Mylan Laboratories Limited, headquartered in Hyderabad, Telangana, specializes in the development and manufacturing of pharmaceutical products. The company is recognized for its expertise in polymorphic forms and hydrochloride salts, focusing on active agents used in various therapeutic areas, including HIV therapy. Mylan's research encompasses innovative pharmaceutical formulations and enzymatic processes, positioning it as a key player in the global pharmaceutical landscape, particularly in the development of essential medications.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Mylan Laboratories Limited USPTO Patent Assignee Logo
42 Patents

#6 in Hyderabad Telangana

#52 in India

#16,374 in the World

Hyderabad Telangana, IN
Hyderabad Telangana, India

Mylan Laboratories Limited

Forward Citations = 19

169 inventors:

goldMedal Ramakoteswara Rao Jetti (10 out of 10 patents)

silverMedal Debashish Datta (5 out of 7 patents)

bronzeMedal Anjaneyaraju Indukuri (4 out of 4 patents)

4.  Vijaya Krishna Ravi (4 out of 4 patents)

5.  Ramesh Dandala (4 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mylan Laboratories Limited. Retrieved from https://idiyas.com/company/mylan-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…